ArticleComputational and mathematical methods in medicine2022
Role of miR-498 Combined with CREB1 in Apoptosis and Invasion of Hepatoma Cell Line.
Article in Computational and mathematical methods in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- Retracted: Role of miR-498 Combined with CREB1 in Apoptosis and Invasion of Hepatoma Cell Line.Computational and mathematical methods in medicine · 2023Article
Corrections and comments
- Retraction · 2023-06-28Concerns/Issues about Data · Concerns/Issues about Referencing/Attributions · Concerns/Issues about Peer Review · Investigation by Journal/Publisher · Investigation by Third Party · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo detect the expression levels of miR-498 in the hepatoma cells and to clarify the biological roles of miR-498 in hepatoma by investigating CREB1, which is the target of miR-498. This study provides a new biomarker for the early diagnosis and targeted therapies for hepatoma.
methodsThe expression of miR-498 between hepatoma cells and hepatocytes was detected by qRT-PCR. miR-498 was overexpressed in hepatoma cells, and then, flow cytometry was used to analyze the cell apoptosis rate. Cell migration and invasion ability were evaluated by Transwell migration assay and Matrigel invasion assay. The downstream targets of miR-498 were searched in the biological database or related software, and the result can be verified by luciferase reporter assay. The knockdown of the downstream target using RNA interference detected its biological functions in hepatoma cells and was confirmed by cotransfection experiments.
resultsmiR-498 was downregulated in hepatoma cell lines compared with hepatocytes. The overexpression of miR-498 significantly promoted apoptosis. Luciferase reporter assays showed that miR-498 could target CREB1 3'UTR and CREB1 was one of the targets of miR-498. Knockdown of CREB1 also inhibited hepatoma cells' malignant potential and increased the apoptosis rate of hepatoma cells. CREB1 was able to alleviate the changes caused by miR-498 overexpression.
conclusionsmiR-498 is downregulated in hepatoma cell lines. Therefore, miR-498 can be one of the potential molecular markers for hepatoma diagnosis. miR-498 plays a role in tumor suppression through regulating CREB1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.